Bristol-Myers Squibb (BMS) will release its Q3 earnings on October 27, following a Q2 revenue increase of 12.9% to $12.97 billion driven by strong sales of Camzyos and its oncology portfolio. Recently, BMS announced positive Phase 3 trial results for RYZ101, showing significant improvement in progression-free survival for certain cancer patients. Despite these advances, BMS stock has declined 2.6% in the past month, trading near $61.6. The company offers a 4.3% yield and trades at a forward EV/EBIT multiple of 9.1x, presenting an attractive risk/reward profile for investors.
Bristol-Myers Squibb (BMY) trades at USD 61.01 on Pluang as of Oct 21, 2026 19:02 WIB, down 1.09% for the day. The stock shows a dividend yield of 4.28% and a market cap of $120.17 billion, with a typical hold time of 92 days among Pluang investors. This trading activity provides current market context ahead of BMY's Q3 earnings release on October 27.
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
Bristol Myers Squibb increased its dividend by 1.6%, marking 17 consecutive years of raises, with a current yield of about 4.2%. Despite strong growth in newer drugs like Camzyos and Eliquis, the company faces challenges from patent expirations, nota...
